卡维地洛联合螺内酯对慢性心力衰竭患者心功能的影响

目的 探讨卡维地洛联合螺内酯对慢性心力衰竭(Chronic heart failure,CHF)患者心功能的影响。方法 选择200例诊断为CHF的患者作为研究对象,采用随机数字表法平均分为观察组与对照组,在常规治疗的基础上分别给予卡维地洛联合螺内酯治疗与单独卡维地洛治疗。随访观察6月,比较两组患者心脏功能、血浆脑钠肽(Brain Natriuretic Peptide,BNP)及谷胱甘肽过氧化物酶(Glutathioneperoxidase,GSH-PX)的差异。结果 观察组总有效率93.0%明显高于对照组84.0%,差异有统计学意义(P<0.05)。治疗后两组LVEF、LVEDD及BNP均较治疗前降低,而LVESD及GSH-PX较治疗前升高,差异有统计学意义(P<0.05)；观察组较对照组改善更明显,差异有统计学意义(P<0.05)。结论 卡维地洛联合螺内酯治疗CHF可以更好改善患者心功能,抑制心肌重塑,降低心衰指标。

Effect of carvedilol combined with spironolactone on cardiac function of patients with chronic heart failure

Objective To study the effect of carvedilol united spironolactone treating cardiac function in patients with chronic heart failure. Methods 200 patients with chronic heart failure were included. All patients were divided into observation group and control group. Patients in observation group were given carvedilol united spironolactone therapy, and patients in control group were given carvedilol therapy. Followed for 6 months, the cardiac function, Brain Natriuretic Peptide (BNP) and Glutathioneperoxidase (gsh-px) were compared. Results The total effective rate in observation group was 93.0%, which was higher than 84.0% in control group. The difference was statistically significant (P < 0.05). The LVEF, LVEDD and BNP after treatment in both groups were lower than that before treatment. The difference were statistically significant (P < 0.05). The LVEF, LVEDD and BNP after treatment in observation group were lower than that in control group. The difference were statistically significant (P < 0.05). The LVESD and gsh-px after treatment in both groups were higher than that before treatment. The difference were statistically significant (P < 0.05). The LVESD and gsh-px after treatment in observation group were higher than that in control group. The difference were statistically significant (P < 0.05). Conclusion Carvedilol united spironolactone therapy in patients with CHF can better improve cardiac function, inhibit myocardial remodeling, and reduce heart failure indicator.